August 15, 2022


Slick Healthy

VGI Health Technology : NAFLD/NASH Phase II Clinical Study

VGI Well being Technology Minimal

ABN: 35 111 082 485

Address: Degree 45, MLC Centre, 19 Martin Area, Sydney NSW 2000 | Tel: +61 2 8279 8908

VGI Wellness Engineering Limited – NAFLD/NASH Period II

Scientific Analyze begins recruitment of sufferers

Sydney, New South Wales, 5 July 2022 – VGI Wellness Technological innovation Limited is happy to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (Invictus), has commenced recruitment of patients for its Stage II clinical research in Non-Alcoholic Fatty Liver Condition (NAFLD)/Non-Alcoholic SteatoHepatitis (NASH).

The research will enrol eighty clients across eight web-sites in Australia, with two web sites The Gallipoli Health care Investigate Basis (GMRF) in Queensland and The Royal Melbourne Clinic in Victoria now commencing recruitment of sufferers.

This examine will be a randomised, double-blind,placebo-controlled Phase II medical review on NAFLD/NASH to analyse the efficacy and protection of IVB001, a drug prospect based mostly on the non- invasive and immediate delivery of tocotrienols applying Invictus‘ patented transmucosal shipping system.

Professor Darrell Crawford, the Director of Research for the GMRF, a Member of the Invictus Scientific Advisory Board and the Affiliate Dean, Strategic Enhancement for the Faculty of Drugs for the University of Queensland, claimed “NAFLD/NASH is a tough and intractable illness to address and there are at present no therapies approved by important regulatory bodies this kind of as the Therapeutic Products Administration right here in Australia or the Foods and Drug Administration in the US. Invictus’ NAFLD/NASH drug prospect, IVB001, has the prospective to handle several areas of this complicated ailment which includes the steatosis (collecting of fat in liver cells), the irritation caused by the steatosis and the fibrosis (scarring triggered by collagen) resulting from the inflammation.”

“There is potent evidence from scientific studies performed by other groups on orally-shipped tocotrienols which clearly show promising indicators of efficacy from NAFLD/NASH and we are of the see that Invictus’ transmucosal shipping and delivery platform would improve this efficacy” commented Dr David Kingston, Invictus’ Main Scientific Officer and Chair of the Scientific Advisory Board.

Additional examine websites are anticipated to commence recruitment of individuals soon and Invictus is advancing preparations for a Phase II medical analyze in Pancreatic Adenocarcimoma (pancreatic cancer) which is expected to start recruitment of people later on this yr.

For extra data remember to get hold of:

Dr Glenn Tong, CEO and Handling Director

Mrs Catriona Glover, Corporation Secretary

Ph: +61 () 412 193 350

Tel: +61 () 402 328 200